Tonix Pharmaceuticals Holding Corp. (TNXP) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$5.28

From 52W high−74.31%

Volume412150.00

Market cap$87.64M

P/E (TTM)—

P/S (TTM)3.0x

Div yield—

Key dataNov 4, 2026

Open

$5.28

From 52W high

−74.31%

Volume

412150.00

Market cap

$87.64M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.6x

P/E (TTM)

—

RSI (14)

19.6

MomentumView details →

1D Return

−1.54%

YTD Return

−67.09%

SummaryUpdated Jun 1, 2026

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Chatham, New Jersey. The company went public in May 2012 and focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics across multiple therapeutic areas. Tonix operates as a development-stage company with a diverse pipeline of drug candidates targeting immunology, rare diseases, infectious diseases, and central nervous system conditions, though it has yet to bring any products to market and remains in the clinical development phase.

Ask drillr about Tonix Pharmaceuticals Holding Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.6x

EV/Sales

−3.0x

P/S (TTM)

3.0x

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

80.25%

Net Margin

−548.64%

EBITDA Margin

−541.35%

ROE (TTM)

−71.83%

ROA (TTM)

−62.84%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

+196.02%

EPS YoY

+20.72%

FCF YoY

—

Revenue CAGR 3Y

+29.90%

EPS CAGR 3Y

+91.75%

EBITDA YoY

−95.02%

MomentumView details →

1D Return

−1.54%

YTD Return

−67.09%

1Y Return

−71.63%

RSI (14)

19.6

vs 50D SMA

−43.33%

vs 200D SMA

−58.20%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

6.61x

Quick Ratio

6.61x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$2.44

EPS Surprise

7.58%

Beats (12Q)

5/12

Next Q EPS Est

−$2.19

Avg Surprise (4Q)

−22.34%

Rev Surprise

75.38%

Financials snapshotView financials →

Revenue (TTM)

29.10M

Net Income (TTM)

−159.67M

Op. CF (TTM)

−154.72M

Next earningsNov 9, 2026 →

Latest newsMore news →

Tonix Pharmaceuticals announced that a poster analyzing Phase 3 data on TONMYA will be presented at the IASP 2026 World Congress on Pain in Bangkok from October 26 to 30, 2026.17d ago

Tonix Pharmaceuticals announced an oral presentation on its investigational TNX-801 vaccine platform and a working group session it will lead at the World Vaccine Congress Europe in Amsterdam on October 19–21, 2026.21d ago

Similar companies

Insight Molecular Diagnostics Inc.IMDX Genelux CorporationGNLX NeurAxis, Inc.NRXS Lixte Biotechnology Holdings, Inc.LIXT Polaryx Therapeutics, Inc. Common StockPLYX Rallybio CorporationRLYB Find similar companies →

Latest newsMore news →

Tonix Pharmaceuticals announced that a poster analyzing Phase 3 data on TONMYA will be presented at the IASP 2026 World Congress on Pain in Bangkok from October 26 to 30, 2026.17d ago Tonix Pharmaceuticals announced an oral presentation on its investigational TNX-801 vaccine platform and a working group session it will lead at the World Vaccine Congress Europe in Amsterdam on October 19–21, 2026.21d ago Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its fibromyalgia treatment TONMYA, effective immediately, adding approximately 21 million Medicare lives.44d ago